454 related articles for article (PubMed ID: 24164900)
1. Therapeutic targeting of the Jak/STAT pathway.
Aittomäki S; Pesu M
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
[TBL] [Abstract][Full Text] [Related]
2. Janus kinases: an ideal target for the treatment of autoimmune diseases.
Gadina M
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S70-2. PubMed ID: 24326567
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.
Liu Y; Holdbrooks AT; De Sarno P; Rowse AL; Yanagisawa LL; McFarland BC; Harrington LE; Raman C; Sabbaj S; Benveniste EN; Qin H
J Immunol; 2014 Jan; 192(1):59-72. PubMed ID: 24323580
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
12. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.
Quan Y; Xu H; Han Y; Mesplède T; Wainberg MA
J Virol; 2017 May; 91(9):. PubMed ID: 28202754
[TBL] [Abstract][Full Text] [Related]
14. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
Durham GA; Williams JJL; Nasim MT; Palmer TM
Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
[TBL] [Abstract][Full Text] [Related]
15. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
16. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
Vafadari R; Weimar W; Baan CC
Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
[TBL] [Abstract][Full Text] [Related]
17. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
18. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
20. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
